VIDEO: Mirikizumab induces, maintains clinical remission at 1 year in UC patients
Click Here to Manage Email Alerts
SAN DIEGO — Patients with ulcerative colitis who responded to mirikizumab at 12 weeks achieved and maintained clinical remission and improved bowel urgency severity at 1 year in the phase 3 LUCENT-2 study.
“The primary endpoint of clinical remission and all key secondary endpoints across clinical, symptomatic, endoscopic and histological measures were met with significance and clinically meaningful effect sizes after 52 weeks of mirikizumab treatment,” Marla C. Dubinsky, MD, professor of pediatrics and medicine at the Icahn School of Medicine at Mount Sinai and co-director of the Susan and Leonard Feinstein Clinical IBD Center, said. “Mirikizumab significantly improved bowel urgency severity compared with placebo, and the overall safety profile was similar to previous phases of studies with mirikizumab in UC and consistent with the safety profile of the other anti-IL-23 p19 antibodies.”
Collapse
Dubinsky M, et al. Abstract 867e. Presented at: Digestive Disease Week; May 21-24, 2022; San Diego (hybrid meeting).
Read more about
Click Here to Manage Email Alerts